Learn More
1008 Background: X, 1,250 mg/m2 bid, d1-14 q21d (Xint) is an approved regimen in MBC, but is associated with dose-limiting toxicities. Thus, we designed this randomized phase II study to investigate(More)
OBJECTIVES Taxanes and anthracyclines are widely used in the treatment of breast cancer, although the benefit is limited to a proportion of patients and predictive biomarkers for clinical outcome(More)
  • 1